• Alas, S., Emmanouilides, C. & Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clinical Cancer Research, 7, 709723.
  • Arnold, D.M., Dentali, F., Crowther, M.A., Meyer, R.M., Cook, R.J., Sigouin, C., Fraser, G.A., Lim, W. & Kelton, J.G. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Annals of Internal Medicine, 146, 2533.
  • Bennett, C.M., Rogers, Z.R., Kinnamon, D.D., Bussel, J.B., Mahoney, D.H., Abshire, T.C., Sawaf, H., Moore, T.B., Loh, M.L., Glader, B.E., McCarthy, M.C., Mueller, B.U., Olson, T.A., Lorenzana, A.N., Mentzer, W.C., Buchanan, G.R., Feldman, H.A. & Neufeld, E.J. (2006) Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 107, 26392642.
  • Blanchette, V. & Bolton-Maggs, P. (2008) Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatric Clinics of North America, 55, 393420, ix.
  • Braendstrup, P., Bjerrum, O.W., Nielsen, O.J., Jensen, B.A., Clausen, N.T., Hansen, P.B., Andersen, I., Schmidt, K., Andersen, T.M., Peterslund, N.A., Birgens, H.S., Plesner, T., Pedersen, B.B. & Hasselbalch, H.C. (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 78, 275280.
  • Cooper, N., Stasi, R., Cunningham-Rundles, S., Feuerstein, M.A., Leonard, J.P., Amadori, S. & Bussel, J.B. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 125, 232239.
  • Cvetkovic, R.S. & Perry, C.M. (2006) Rituximab – a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 66, 791820.
  • Flieger, D., Renoth, S., Beier, I., Sauerbruch, T. & Schmidt-Wolf, I. (2000) Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cellular Immunology, 204, 5563.
  • Garcia Hernandez, F.J., Ocana Medina, C., Gonzalez Leon, R., Garrido Rasco, R., Colorado Bonilla, R., Castillo Palma, M.J. & Sanchez Roman, J. (2007) [Rituximab for treatment of patients with systemic autoimmune diseases]. Medicina Clínica (Barc), 128, 458462.
  • Garcia-Chavez, J., Majluf-Cruz, A., Montiel-Cervantes, L., Esparza, M.G. & Vela-Ojeda, J. (2007) Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Annals of Hematology, 86, 871877.
  • Garvey, B. (2008) Rituximab in the treatment of autoimmune haematological disorders. British Journal of Haematology, 141, 149169.
  • Godeau, B., Fain, O., Porcher, R., Lefrere, F., Fenaux, P., Cheze, S., Vekhoff, A., Chauveheid, M.P., Stirnemann, J., Galicier, L., Bourgeois, E., Haiat, S., Varet, B., Leporrier, M., Papo, T., Michel, M. & Bierling, P. (2006) Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: Results of a multicenter prospective phase 2 study. Blood, 108, (ASH Annual Meeting Abstracts), 145A.
  • Kalpatthi, R. & Bussel, J.B. (2008) Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Current Opinion in Pediatrics, 20, 816.
  • Parodi, E., Nobili, B., Perrotta, S., Rosaria Matarese, S.M., Russo, G., Licciardello, M., Zecca, M., Locatelli, F., Cesaro, S., Bisogno, G., Giordano, P., De Mattia, D. & Ramenghia, U. (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. International Journal of Hematology, 84, 4853.
  • Penalver, F.J., Jimenez-Yuste, V., Almagro, M., Alvarez-Larran, A., Rodriguez, L., Casado, M., Gallur, L., Giraldo, P., Hernandez, R., Menor, D., Rodriguez, M.J., Caballero, D., Gonzalez, R., Mayans, J., Millan, I. & Cabrera, J.R. (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Annals of Hematology, 85, 400406.
  • Provan, D., Butler, T., Evangelista, M.L., Amadori, S., Newland, A.C. & Stasi, R. (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica, 92, 16951698.
  • Rao, A., Kelly, M., Musselman, M., Ramadas, J., Wilson, D., Grossman, W. & Shenoy, S. (2008) Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatric Blood & Cancer, 50, 822825.
  • Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B-cells in-vivo by a chimeric mouse-human monoclonal-antibody to CD20. Blood, 83, 435445.
  • Shan, D., Ledbetter, J.A. & Press, O.W. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunology, Immunotherapy, 48, 673683.
  • Stasi, R., Pagano, A., Stipa, E. & Amadori, S. (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 98, 952957.
  • Taube, T., Schmid, H., Reinhard, H., Von Stackelberg, A., Henze, G. & Overberg, U.S. (2005) Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica, 90, 281283.
  • Taylor, R.P. & Lindorfer, M.A. (2007) Drug insight: the mechanism of action of rituximab in autoimmune disease – the immune complex decoy hypothesis. Nature Clinical Practice Rheumatology, 3, 8695.
  • Wang, J., Wiley, J.M., Luddy, R., Greenberg, J., Feuerstein, M.A. & Bussel, J.B. (2005) Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. Journal of Pediatrics, 146, 217221.